The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase
- 1 July 2004
- journal article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 319 (4), 1272-1275
- https://doi.org/10.1016/j.bbrc.2004.05.113
Abstract
No abstract availableFunding Information
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 21 references indexed in Scilit:
- The BCR-ABL Story: Bench to Bedside and BackAnnual Review of Immunology, 2004
- Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemiaBlood, 2003
- Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatmentBlood, 2002
- Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571Published by Elsevier BV ,2002
- A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemiasBlood, 2002
- Imatinib Mesylate — A New Oral Targeted TherapyNew England Journal of Medicine, 2002
- CrkL Is Recruited through Its SH2 Domain to the Erythropoietin Receptor and Plays a Role in Lyn-mediated Receptor SignalingPublished by Elsevier BV ,2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- STAT signaling in the pathogenesis and treatment of leukemiasOncogene, 2000
- An Activating Mutation in the ATP Binding Site of the ABL Kinase DomainPublished by Elsevier BV ,1996